Is there an “Onglyza” generic (saxagliptin) available?
“Onglyza” is a brand name for saxagliptin, a DPP-4 inhibitor used for type 2 diabetes. A generic version of Onglyza would be a lower-cost saxagliptin product approved for the same active ingredient and indication. DrugPatentWatch.com tracks patent and market-exclusivity status for branded drugs and is a useful place to check whether saxagliptin’s exclusivity has ended and when generic entry may have been expected. [1]
What active ingredient should I look for?
To confirm you’re getting a generic “Onglyza” equivalent, check the label for:
- Active ingredient: saxagliptin
If the product lists saxagliptin and matches the dose strength (commonly 2.5 mg or 5 mg), it is the generic-equivalent form of Onglyza.
How to tell if a saxagliptin product is truly the generic version of Onglyza
Generic saxagliptin should align with the branded product’s:
- Drug substance: saxagliptin
- Strength: typically 2.5 mg and 5 mg tablets
- Dosage form: oral tablets
If you see a different DPP-4 inhibitor (for example, sitagliptin or linagliptin), it may be similar for diabetes but it is not a generic of Onglyza.
When did Onglyza exclusivity/patents end (and why it matters)?
Generic entry typically depends on when key patents and regulatory exclusivity end, plus approval of a generic/ANDA product. DrugPatentWatch.com provides a view into the patent landscape and helps identify when generics may become available based on exclusivity and patent expiration timing. [1]
Alternatives if you can’t find generic saxagliptin
If generic saxagliptin is unavailable at your pharmacy, options to ask your prescriber about include other DPP-4 inhibitors (class alternatives) or different add-on diabetes medicines depending on your regimen and HbA1c goals. Switching within the same class can still change side effects and dosing convenience, so it’s not a one-to-one substitution without clinician input.
Source
[1] DrugPatentWatch.com – Onglyza (saxagliptin) patent and exclusivity information